Deborah Gleeson

Trump is toying with us, but his 200% tariff threat could still harm sick Australians A restriction on the supply of generic medicines to Australia is among genuine risks, regardless of the eventual tariff on pharmaceuticals.

My thoughts about Trump's threat to slap tariffs of up to 200% on pharmaceuticals: www.theage.com.au/national/tru...

Trump 2.0: Potentially the worst development in three decades for access to medicines? www.globe.uio.no/english/rese...

The PBS targeted in Trump’s trade war: experts fear long term fall out for drug prices and access - InSight+ As the Trump administration continues its program of “reciprocal tariffs” and the pharmaceutical industry calls out the Pharmaceutical Benefits Scheme (PBS) and generic drugs, Australian health expert...

Last week I spoke with Becca Whitehead from MJA Insight about Trump, trade and access to generics in Australia. insightplus.mja.com.au/2025/14/the-...

Trump has Australia’s generic medicines in his sights. And no-one’s talking about it The major parties say they won’t use the PBS as a bargaining chip in US tariff negotiations. They also need to resist pressure to slow down access to generic drugs.

What claims is the Trump Administration making about barriers to trade for its pharmaceutical companies in Australia? Spoiler alert: it's not the PBS, exactly, but the timing of when drug makers find out a generic copy of their product is planning to launch. theconversation.com/trump-has-au...

I have an exciting PhD scholarship opportunity to share for an interdisciplinary project on 'The Political Economy of the Pharmaceutical Innovation System in the UK and Australia and Access to Medical Products for Pandemics'! More information: www.latrobe.edu.au/study/schola...